Macquarie Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.9M Sell
37,980
-2,256
-6% -$1,000K 0.08% 194
2026
Q1
$18M Sell
40,236
-4,500
-10% -$2.1M 0.11% 167
2025
Q4
$20.3M Sell
44,736
-178,820
-80% -$77.1M 0.09% 179
2025
Q3
$87.6M Sell
223,556
-5,297
-2% -$2.21M 0.1% 264
2025
Q2
$102M Sell
228,853
-5,283
-2% -$2.43M 0.13% 226
2025
Q1
$114M Buy
234,136
+4,203
+2% +$1.96M 0.14% 202
2024
Q4
$88.7M Sell
229,933
-96,583
-30% -$44.8M 0.11% 265
2024
Q3
$152M Sell
326,516
-9,229
-3% -$4.43M 0.16% 161
2024
Q2
$157M Sell
335,745
-36,496
-10% -$15.8M 0.18% 143
2024
Q1
$156M Sell
372,241
-25,053
-6% -$10.6M 0.18% 151
2023
Q4
$162M Sell
397,294
-333,639
-46% -$123M 0.19% 137
2023
Q3
$254M Buy
730,933
+16,498
+2% +$5.77M 0.32% 57
2023
Q2
$251M Sell
714,435
-51,939
-7% -$17.5M 0.29% 61
2023
Q1
$241M Sell
766,374
-92,926
-11% -$27.9M 0.29% 65
2022
Q4
$248M Sell
859,300
-38,008
-4% -$11.6M 0.29% 60
2022
Q3
$260M Sell
897,308
-35,871
-4% -$10.3M 0.32% 59
2022
Q2
$263M Buy
933,179
+652,321
+232% +$175M 0.3% 64
2022
Q1
$73.3K Sell
280,858
-23,399
-8% -$5.55M 0.06% 396
2021
Q4
$66.8M Sell
304,257
-1,046,258
-77% -$203M 0.06% 427
2021
Q3
$245M Sell
1,350,515
-266,259
-16% -$52M 0.21% 100
2021
Q2
$326M Buy
1,616,774
+1,466,287
+974% +$307M 0.27% 79
2021
Q1
$32.3M Buy
150,487
+14,384
+11% +$3.16M 0.05% 430
2020
Q4
$32.2M Buy
136,103
+5,739
+4% +$1.32M 0.05% 402
2020
Q3
$35.5M Buy
130,364
+19,437
+18% +$5.36M 0.06% 339
2020
Q2
$32.2M Buy
110,927
+1,807
+2% +$490K 0.06% 357
2020
Q1
$26M Sell
109,120
-15,009
-12% -$3.44M 0.05% 356
2019
Q4
$27.2M Sell
124,129
-15,512
-11% -$3.14M 0.04% 428
2019
Q3
$23.7M Buy
139,641
+3,050
+2% +$540K 0.04% 418
2019
Q2
$25M Sell
136,591
-19,219
-12% -$3.36M 0.04% 407
2019
Q1
$28.7M Sell
155,810
-3,540
-2% -$654K 0.05% 385
2018
Q4
$26.4M Buy
159,350
+5,713
+4% +$990K 0.05% 364
2018
Q3
$29.6M Sell
153,637
-13,490
-8% -$2.4M 0.05% 387
2018
Q2
$28.4M Sell
167,127
-13,605
-8% -$2.11M 0.05% 403
2018
Q1
$29.5M Buy
180,732
+12,459
+7% +$2.04M 0.05% 371
2017
Q4
$24.9M Sell
168,273
-56,001
-25% -$8.29M 0.04% 423
2017
Q3
$34.1M Buy
224,274
+16,927
+8% +$2.55M 0.06% 323
2017
Q2
$26.7M Sell
207,347
-3,048
-1% -$367K 0.05% 378
2017
Q1
$23M Sell
210,395
-25,252
-11% -$2.22M 0.04% 422
2016
Q4
$17.4M Sell
235,647
-28,449
-11% -$2.31M 0.03% 476
2016
Q3
$23M Sell
264,096
-263,536
-50% -$24.9M 0.04% 367
2016
Q2
$45.4M Buy
527,632
+239,951
+83% +$20.7M 0.04% 339
2016
Q1
$22.9M Buy
287,681
+38,051
+15% +$3.44M 0.05% 312
2015
Q4
$31.4M Buy
249,630
+8,940
+4% +$1.08M 0.06% 258
2015
Q3
$25.1M Buy
240,690
+78,650
+49% +$10.1M 0.05% 295
2015
Q2
$20M Sell
162,040
-64,317
-28% -$8.1M 0.04% 363
2015
Q1
$26.7M Buy
226,357
+6,347
+3% +$760K 0.05% 328
2014
Q4
$26.1M Sell
220,010
-11,195
-5% -$1.26M 0.05% 332
2014
Q3
$26M Sell
231,205
-18,334
-7% -$1.75M 0.06% 321
2014
Q2
$23.6M Sell
249,539
-110,020
-31% -$7.71M 0.05% 328
2014
Q1
$25.4M Buy
359,559
+35,110
+11% +$2.78M 0.04% 300
2013
Q4
$24.1M Sell
324,449
-1,320
-0.4% -$91.9K 0.04% 297
2013
Q3
$24.7M Buy
325,769
+2,400
+0.7% +$191K 0.05% 286
2013
Q2
$25.8M Buy
+323,369
New +$23.8M 0.06% 263

Other funds holding VRTX

Macquarie Group's VRTX Position: Q2 2026 in Review

Macquarie Group reduced its Vertex Pharmaceuticals (VRTX) stake by 5.6% in Q2 2026, selling an estimated $1,000K and leaving 37,980 shares worth $18.9M. The position accounts for 0.08% of the portfolio, ranked #194.

Macquarie Group first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $326M in Q2 2021. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Macquarie Group held 37,980 shares of Vertex Pharmaceuticals worth $18.9M as of Q2 2026.
  • Macquarie Group sold 2,256 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1,000K.
  • Vertex Pharmaceuticals made up 0.08% of Macquarie Group's portfolio in Q2 2026, its #194 holding.
  • Macquarie Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Macquarie Group's Vertex Pharmaceuticals position peaked at $326M in Q2 2021.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.